Oral NMN costs about $25 to $45 a month in capsules at a common 250 to 500 mg daily dose, as of October 2026; bulk powder can bring that under $10. Compare brands by cost per gram: capsules run about $3 a gram, bulk powder about $0.55. Since September 2025 the FDA accepts NMN as a lawful dietary supplement.
“How much does NMN cost?” looks like a simple question and isn’t, because the number on the bottle hides two things that decide what you actually pay: the dose you take and the purity you get. NMN is an oral supplement, so unlike an IV drip or a compounded injection there’s no clinic time baked into the price — the whole cost is the powder in the capsule. That makes NMN a pure price-per-effective-dose problem, plus a regulatory wrinkle worth knowing even though it's now resolved: in the United States, whether NMN could even be sold as a supplement was an open question until the FDA reversed itself in September 2025. Here’s what a month of NMN runs in October 2026, how to compare brands honestly, the regulatory history you should know about, and how to match the spend to what the science actually supports.
~$25–$45/mo
Oral NMN capsules at common 250–500 mg/day doses (bulk powder under $10)
sellers' public pricing, October 2026
Cost per gram
The metric that actually compares brands
Lawful
U.S. dietary-supplement status of NMN, per FDA's Sept. 2025 reversal
What a month of NMN actually costs
Strip away the marketing and NMN is a white powder sold by the gram. As of October 2026, a mainstream NMN capsule at a common daily dose (roughly 250 to 500 mg a day) costs about $25 to $45 a month bought one bottle at a time. On one brand’s own store, for example, 30 capsules of 300 mg cost $26.95 (about $3.00 a gram) and 30 servings of 500 mg cost $42.95 (about $2.86 a gram). Bulk powder is far cheaper per gram: another seller lists 100 g of pure NMN powder for $54.95, about $0.55 a gram, or under $10 a month at 500 mg a day if you measure it yourself. Blends with resveratrol or other add-ons, liposomal versions and high-dose capsules cost more. That band is wide for a reason: two bottles at the same sticker price can deliver very different amounts of NMN. One might be 60 capsules at 250 mg (a month at one-a-day, two weeks at the more common two-a-day); another might be 30 capsules at 500 mg. The shelf price tells you almost nothing until you convert it.
Why purity and testing belong in the price
Cost per gram only means something if the gram is real. NMN is an unstable molecule and an attractive one to cut, so a bargain powder can list 500 mg per serving and assay lower, or carry impurities that the label never mentions. The defensible premium in this category is paid for third-party testing — a certificate of analysis confirming identity, the stated dose, and the absence of contaminants. A brand that publishes batch testing and one that doesn’t are not selling the same product at different prices; they’re selling different products. When you compute cost per gram, compute it on the verified gram, and treat an untested cut-rate powder the way you’d treat any unverified supplement: the low number is only a bargain if the contents match the claim.
The regulatory cloud over NMN — lifted in September 2025
Here is a twist that made NMN’s cost story different from any other longevity capsule — and then resolved. In late 2022 the U.S. Food and Drug Administration took the position that NMN was excluded from the legal definition of a dietary supplement — the agency’s reasoning being that NMN had been authorized for investigation as a new drug before it was marketed as a supplement, which under the statute can knock an ingredient out of supplement status.[3] The agency never pulled NMN from shelves, and it remained widely and openly sold throughout, but the legal question hung over the category for nearly three years.
That cloud has since lifted. In two letters dated September 29, 2025, the FDA reversed its position, concluding that NMN was in fact marketed as a dietary supplement before it was authorized for drug investigation — the opposite factual finding from 2022 — and is therefore not excluded from the dietary-supplement definition after all.[4] The reversal answered a citizen petition from the Natural Products Association and the Alliance for Natural Health USA, which the FDA granted in part; the trade group had also sued the agency. The FDA did not accept every argument: it rejected the claim that NMN needs no New Dietary Ingredient (NDI) notification at all. Practically, NMN now goes through the standard NDI pathway like any other new supplement ingredient, and sellers no longer operate under the earlier exclusion.
For a buyer, this still matters in one practical way: the NMN-versus-NR decision below is less lopsided than it was — NR still has the longer, cleaner regulatory track record, but NMN is no longer selling under an active exclusion. None of this was ever a claim that NMN is unsafe; it was a claim that the rules around it were unsettled, and as of late 2025 they are meaningfully more settled.
NMN vs. NR: the value question behind the price
The two leading oral NAD+ precursors are NMN and nicotinamide riboside (NR), and the choice between them is partly a value calculation. NR — sold most prominently as the patented ingredient Niagen — was commercialized through the supplement framework and has the longer, more-established regulatory track record; NMN spent nearly three years under the FDA’s now-reversed exclusion before the agency confirmed in September 2025 that it is not excluded from the dietary-supplement definition after all. On the evidence side the two are close cousins: both reliably raise blood NAD+ in randomized human trials, and neither has shown that doing so extends human healthspan. We compare the underlying trial data head-to-head in our NAD+ precursors (NR and NMN) evidence review, and the NAD+ format comparator lays the routes side by side on cost and convenience. The short version: NMN often wins on raw per-gram price, NR still has the longer track record, and the regulatory gap between them has narrowed since the FDA's reversal.
Swipe to see all columns
| Oral precursor | Typical monthly cost (October 2026) | Regulatory & evidence note |
|---|---|---|
| NMN (capsule or powder) | ~$25–$45 in capsules at 250–500 mg/day; under $10 as bulk powder | FDA reversed its 2022 exclusion in Sept. 2025, so it is no longer excluded from the supplement definition; raises blood NAD+ in RCTs on surrogate endpoints |
| NR (e.g. patented Niagen) | About $49 at 300 mg/day (one bottle at a time; ~$39 on subscription) | Longer-established regulatory track record; RCTs show it raises blood NAD+ |
Cost versus evidence: what your money is really buying
The organizing principle for NMN spending is the same one that governs the whole NAD+ category: you are buying a biomarker, not an outcome. The headline NMN trial that everyone cites enrolled postmenopausal women with prediabetes and found a gain in muscle insulin sensitivity among those taking the compound — a real, peer-reviewed randomized result, but a small one, in a narrow population, on a surrogate measure rather than a hard clinical outcome: 25 women, 250 mg a day for 10 weeks, muscle insulin sensitivity up 25%.[1] A larger, dose-ranging randomized, double-blind, placebo-controlled trial in 80 healthy middle-aged adults (300, 600 or 900 mg a day for 60 days) found NMN well tolerated; blood NAD rose in every NMN group versus placebo (p ≤ 0.001), most at 600 and 900 mg, and six-minute walk distance improved, while insulin resistance (HOMA-IR) did not change — again, useful and reassuring on safety, and again on modest, surrogate endpoints rather than proof of a longer or healthier life.[2] That evidence tier is exactly what should set your budget: NMN is supplement-priced for supplement-grade evidence, and paying premium-longevity prices for it assumes a benefit the trials have not shown. To see how NMN stacks up against other interventions on that score, our longevity evidence matrix grades it so you’re not paying outcome prices for biomarker data.
How NMN fits the wider NAD+ cost picture
Oral NMN is the cheapest seat in the NAD+ category by a wide margin. The same molecule’s coenzyme can be sold as a subcutaneous NAD+ injection or an IV drip, where the price climbs into the hundreds of dollars a month or per session — and, paradoxically, the controlled-outcome evidence gets thinner as the bill gets bigger. The only human study of an intravenous infusion of the coenzyme tracked how quickly it left the plasma, not any clinical benefit; we walk through that in NAD+ IV therapy and the evidence it’s priced ahead of. So an oral NMN capsule isn’t just the budget option — for the core claim of raising blood NAD+, it’s the route with the strongest human data attached to the lowest price. If you do want a clinician-supervised program, our NAD+ therapy provider list sets out the options so you can pair what you pay with the care model on offer.
The honest bottom line
A month of oral NMN realistically costs about $25 to $45 in capsules at common doses (less as bulk powder), but the only number that lets you compare brands is cost per gram of verified NMN — run that calculation and most of the price confusion disappears. The U.S. regulatory cloud that used to temper the bargain-hunting has lifted: the FDA reversed its 2022 exclusion in September 2025, and NMN is no longer selling under that legal cloud. What still matters is the evidence tier, which is genuine but surrogate-marker-level, and NR's longer regulatory track record if that history matters to you. Pay NMN like the supplement it is — priced per effective gram, bought from a brand that proves what’s in the bottle, and anchored to evidence that shows a moved biomarker, not a longer life.
